MedPath

AbbVie Writes Off $3.5B on Cerevel Drug After Phase 2 Failures

AbbVie has decided to write off $3.5 billion invested in a Cerevel drug following unsuccessful Phase 2 clinical trials.

AbbVie has announced a significant financial write-off of $3.5 billion related to a drug developed by Cerevel Therapeutics, following the drug's failure in Phase 2 clinical trials. This decision underscores the challenges and risks associated with drug development, particularly in the later stages of clinical testing. The write-off reflects the company's reassessment of the drug's potential in light of the trial outcomes, marking a pivotal moment in AbbVie's investment and development strategy.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Eli Lilly's Omvoh (mirikizumab) for Crohn's Disease and Roche's Susvimo Implant for Diabetic Macular Edema

Eli Lilly's Omvoh (mirikizumab) has received FDA approval for treating moderate to severe Crohn's disease in adults, marking a new option targeting the IL-23 pathway.
Roche's Susvimo implant has been re-approved by the FDA for diabetic macular edema (DME), offering a long-term treatment alternative with reduced injection frequency.

Regor's Obesity Pill Shows Modest Weight Loss in Phase 2a, Advances to New Trial

Regor's obesity treatment has demonstrated modest weight loss results in its Phase 2a trial and is now moving forward into a new clinical trial.

Pfizer's Sasanlimab Shows Promise in Bladder Cancer Treatment

Pfizer's sasanlimab, a PD-1 inhibitor, combined with standard therapy, significantly delayed death and disease complications in bladder cancer patients.
The Phase 3 trial results position sasanlimab as a potential competitor to existing immunotherapies like Merck's Keytruda and Bristol Myers Squibb's Opdivo.

AbbVie Reassesses Emraclidine's Future After Phase II Schizophrenia Trial Failures

AbbVie's emraclidine failed to meet primary endpoints in Phase II trials for schizophrenia, leading to a $3.5 billion impairment charge and a reevaluation of its development path.
The company is now focusing on emraclidine as an adjunctive treatment for schizophrenia and as a monotherapy for psychosis related to Alzheimer's and Parkinson's diseases.

Advancements in Clinical Trials: Cell Therapies for Parkinson's, Protein Degraders for IgAN, High-Dose Wegovy, Schizophrenia Treatment, and Stem Cell Therapy for IVF

BlueRock Therapeutics, a Bayer subsidiary, is advancing its cell therapy for Parkinson's disease directly to a Phase 3 trial, aiming to provide a novel treatment option.
Biohaven is moving its protein degrader for IgA nephropathy (IgAN) into Phase 3 trials after promising early results, addressing a significant unmet need in kidney disease.

Acelyrin's Stock Drops Due to Mixed Phase 2 Data

Acelyrin reports mixed results from Phase 2 trials of a potential treatment for thyroid eye disease, leading to a drop in stock prices.

Bristol Myers' TYK2 Inhibitor Shows Promise in Phase 3 Psoriatic Arthritis Trials

Bristol Myers Squibb's TYK2 inhibitor has demonstrated success in a pair of Phase 3 clinical trials targeting psoriatic arthritis, marking a significant advancement in the treatment of this condition.

AbbVie's Emraclidine Fails in Phase II Schizophrenia Trials, Shares Plummet

AbbVie's emraclidine failed to demonstrate statistically significant improvement in schizophrenia symptoms compared to placebo in two Phase II trials.
The failure led to a 12% drop in AbbVie's shares, raising concerns about the company's long-term growth strategy and neuroscience pipeline.

AbbVie's Emraclidine Fails in Phase 2 Schizophrenia Trials, Benefiting BMS

AbbVie's emraclidine failed to show improvement over placebo in two Phase 2 trials (EMPOWER 1 and 2) for schizophrenia, impacting AbbVie's stock value.
Emraclidine, a selective muscarinic M4 receptor-positive allosteric modulator (PAM), aimed to improve tolerability compared to current antipsychotics.

Sanofi Highlights Phase 3 Sarclisa Data in Multiple Myeloma Treatment

Sanofi has recently showcased promising Phase 3 data for its Sarclisa treatment in multiple myeloma, aiming to compete with J&J's Darzalex.

Reference News

[1]
AbbVie writes off $3.5B on Cerevel drug after Phase 2 failures - Endpoints News
endpts.com · Jan 10, 2025

Endpoints subscribers can request a magic link for password-free login, valid once for 24 hours. Alternatively, a passwo...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy